Monitor upcoming regulatory updates or label expansions for CARVYKTI in earlier lines, as well as competitive CAR-T data from Bristol Myers Squibb (Breyanzi) and Johnson & Johnson's own pipeline. The small cohort size (n=20) limits statistical power, but the durability signal is positive for Legend's long-term market position.
Price Chart
Executive Summary
Legend Biotech presented five-year follow-up data from CARTITUDE-2 Cohort A at IMS 2026, showing 50% of patients remained alive and progression-free after a single CARVYKTI infusion without maintenance therapy, with a five-year overall survival rate of 69.2%. These long-term data strengthen the curative potential narrative for CARVYKTI in earlier-line relapsed/refractory multiple myeloma, but the small cohort (n=20) and absence of new commercial or regulatory catalysts limit immediate stock impact.
Key Facts
- Five-year overall survival rate of 69.2% in CARTITUDE-2 Cohort A (n=20) with median follow-up of 60.7 months
- 50% of patients (10/20) remained alive and progression-free without maintenance therapy at five years
- Median progression-free survival was 60.5 months; median overall survival was not reached
- No new CAR T-cell-related neurotoxicity reported; safety profile consistent with known profile
- One new hematologic malignancy (acute myeloid leukemia) and two deaths (progressive disease and new cancer) since prior analysis at ~30 months
Financial Impact
No financial figures provided in the release; data reinforces CARVYKTI's long-term efficacy profile in earlier-line RRMM, which supports ongoing commercial adoption but does not quantify revenue impact
Risk Factors
- Small sample size (n=20) limits generalizability of the five-year data
- Safety concerns remain: one new hematologic malignancy and two deaths reported since prior analysis
- No new regulatory or commercial catalyst announced; stock impact may be muted without near-term milestone
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.37 (+2.88%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.37 (+13.93%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.37 (+8.24%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.37 (+6.59%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.37 (+6.59%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.37 (+15.28%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.37 (+9.93%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.37 (−6.69%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.37 (−5.71%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.37 (+5.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers